drugset / Trial / NCT00285376

Effectiveness Study of Vilazodone to Treat Depression and to Discover Genetic Markers Associated With Response

NCT00285376

Phase 3 Completed 410 enrolled Genaissance Pharmaceuticals
RandomizedParallel-groupQuadruple-blindTreatment

Summary

This study is designed to determine the safety and effectiveness of vilazodone for major depressive disorder and to discover genetic markers associated with response. This study will enroll approximately 400 patients.

Timeline

Start
2006-02
Primary completion
2007-05
Completion
2007-05

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Vilazodone Small molecule 40 mg